Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus
Open Access
- 17 August 2023
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (4) , e0219923
Abstract
The protein synthesis inhibitor linezolid is used for the treatment of lung disease caused by Mycobacterium abscessus . However, many strains of the bacterium show poor susceptibility to the antibiotic.Keywords
Funding Information
- HHS | National Institutes of Health (R01AI132374)
This publication has 20 references indexed in Scilit:
- Molecular Analysis of Linezolid-Resistant Clinical Isolates of Mycobacterium abscessusAntimicrobial Agents and Chemotherapy, 2019
- Mechanistic and Structural Insights Into the Unique TetR-Dependent Regulation of a Drug Efflux Pump in Mycobacterium abscessusFrontiers in Microbiology, 2018
- In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2017
- Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384Antimicrobial Agents and Chemotherapy, 2017
- Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environmenteLife, 2017
- Selection of Resistance to Clarithromycin in Mycobacterium abscessus SubspeciesAntimicrobial Agents and Chemotherapy, 2017
- Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2016
- Secondary structure and domain architecture of the 23S and 5S rRNAsNucleic Acids Research, 2013
- Ribosomal and non‐ribosomal resistance to oxazolidinones: species‐specific idiosyncrasy of ribosomal alterationsMolecular Microbiology, 2002
- Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilutionClinical Microbiology and Infection, 2000